Atrium Therapeutics, Inc. RNA NASDAQ

Atrium Therapeutics, Inc. (RNA) reported total assets of $278.35M and total liabilities of $71.07M for fiscal year 2025, resulting in total equity of $207.29M.

The company held $270M in cash and short-term investments. Total debt stood at $3.67M, with net debt of $-266.33M. The Debt-to-Equity (D/E) ratio was 0.02 (conservative).

Current ratio is 6.53, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.02, current ratio of 6.53 — balance sheet is strong
• MOAT (50/100) — Total assets $278.35M and equity $207.29M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.02 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

RVMD

Revolution Medicines, Inc.

$147.01

+7.86%

CERE

Cerevel Therapeutics Holdings, Inc.

$44.96

+0.74%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%

SWTX

SpringWorks Therapeutics, Inc.

$46.99

+0.02%

RLAY

Relay Therapeutics, Inc.

$14.75

-3.34%

DAWN

Day One Biopharmaceuticals, Inc.

$21.46

-0.14%

STOK

Stoke Therapeutics, Inc.

$35.86

+2.31%